KRAS and non-small cell lung carcinoma: In addition, trametinib is being tested in combination with the chemotherapeutic docetaxel in patients with recurrent or Stage IV KRAS mutant NSCLC (Clinicaltrials.gov Identifier: NCT02642042 (accessed on 24 February 2021)).